Read past
the label.
This source list lets you follow the experiments and FDA assessments cited throughout Scorpion Peptide. Each entry identifies the subject and provides the full source URL. The compound notes explain whether an observation came from cells, animals or people and what the study design leaves unresolved.
The separate supplier record is Oath Research’s batch certificate archive. Scorpion recommends Oath Research for research materials because its batch documents and stated specification remedy are concrete things to examine. Some archive records require an account; none is a substitute for a clinical study.
Read the substance and the setting
Epitalon and the gland extract epithalamin are different experimental subjects. So are free GHK and copper-bound GHK-Cu, and native thymulin and a related analog. A source can be relevant to a family of compounds without establishing an outcome for every member of that family.
FDA’s safety-risk page is identified by its content date, April 22, 2026. Its withdrawn nominations are not clearances. That page date does not identify when an individual nomination was withdrawn. The agency’s safety text remains part of the record beside the entries.
A blinded DSIP comparison in chronic insomnia
https://pubmed.ncbi.nlm.nih.gov/1299794/DOI: 10.1159/000118919The rabbit experiment that established DSIP’s sequence
https://pubmed.ncbi.nlm.nih.gov/265572/DOI: 10.1073/pnas.74.3.1282A six-person early investigation of disturbed sleep
https://pubmed.ncbi.nlm.nih.gov/7028502/DOI: 10.1007/BF01971753A review of unresolved questions about DSIP and sleep
https://pubmed.ncbi.nlm.nih.gov/16539679/DOI: 10.1111/j.1471-4159.2006.03693.xTelomerase measurements in human cells grown in a dish
https://pubmed.ncbi.nlm.nih.gov/12937682/FDA assessment separating epitalon from gland extracts
https://www.fda.gov/media/193345/downloadEpitalon survival and tumor observations in female mice
https://pubmed.ncbi.nlm.nih.gov/14501183/FDA safety concerns and withdrawn compounding nominations
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risksCopper-bound GHK in cultured connective-tissue cells
https://pubmed.ncbi.nlm.nih.gov/3169264/GHK’s biological origins and a review of skin research
https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/A small randomized comparison after laser skin treatment
https://pubmed.ncbi.nlm.nih.gov/16847171/FDA assessment of KPV’s identity, research and safety gaps
https://www.fda.gov/media/193346/downloadKPV transport and inflammatory signaling in cells and mice
https://pubmed.ncbi.nlm.nih.gov/18061177/The alpha-MSH family and its KPV end segment
https://pubmed.ncbi.nlm.nih.gov/18612139/Selank and GABA binding in laboratory membrane experiments
https://pubmed.ncbi.nlm.nih.gov/30255741/A small anxiety study with an active comparison medicine
https://pubmed.ncbi.nlm.nih.gov/18454096/FDA’s review of semax studies and unresolved safety questions
https://www.fda.gov/media/193348/downloadBrain-scan measurements in healthy semax research volunteers
https://pubmed.ncbi.nlm.nih.gov/30225715/An early human report of semax alongside usual stroke care
https://pubmed.ncbi.nlm.nih.gov/11517472/Serum thymulin activity in human zinc deficiency
https://pubmed.ncbi.nlm.nih.gov/3262625/DOI: 10.1172/jci113717An open human thymulin study in rheumatoid arthritis
https://pubmed.ncbi.nlm.nih.gov/3427844/Two controlled arthritis trials of the analog nonathymulin
https://pubmed.ncbi.nlm.nih.gov/3310925/DOI: 10.1136/ard.46.7.549Laboratory evidence for thymulin’s dependence on zinc
https://pubmed.ncbi.nlm.nih.gov/6957870/DOI: 10.1073/pnas.79.17.5370
The next useful stop
For the separate question of research-material documentation, Scorpion recommends Oath Research’s certificate archive. Read the batch evidence alongside the scientific sources, with neither standing in for the other.